fashion -WSS

fashion

author：knowledge 2025-09-30 16:28:36 - browse：86557

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Appeals court upholds limits to abortion pill

WSS

Stop Congress from blocking public access to science

2024 GOP presidential candidates spar over abortion in debate

Medicare innovation center doesn’t save money, experts say

AstraZeneca bets AAV gene therapy will still deliver the goods

How Long Island became the ‘eugenics capital of the world’

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

hotspot

fashion

focus

Novavax promises a turnaround & Lilly roils the obesity market

Health insurers' Q3 question: how much care are people getting?

The high cost of giving birth even with insurance

AstraZeneca bets AAV gene therapy will still deliver the goods

FDA approval of Sarepta Duchenne genetic therapy gives me hope

2024 GOP presidential candidates spar over abortion in debate

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How a symptom of dementia informs our understanding of creativity

The high cost of giving birth even with insurance

How to make Best Hospitals ratings actually useful for patients

leisure time

The Karikó problem: Lessons for funding basic research

New oral drug delivery patch is modeled after octopus tentacles

New oral drug delivery patch is modeled after octopus tentacles

Medicare innovation center doesn’t save money, experts say

With Roe v Wade overturned, abortion providers work to adapt

With Roe v Wade overturned, abortion providers work to adapt

entertainment

focus

focus

hotspot